| 摘要 |
A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity. |
